 "Check out Ranbaxy's regulatory problems in India in this interactive map")
Sun Pharmaceutical Industries on Monday agreed to buy its troubled peer Ranbaxy for $4 billion in stock, ending its ill-fated six-year control by Japan’s Daiichi Sankyo.
Daiichi Sankyo bought Ranbaxy in 2008, believing its dominance in cheap generic medicines and developing markets would help the firm grow. But the Indian company has been a weight on Daiichi’s books ever since due to its regulatory problems.
The United States, one of Ranbaxy Laboratories’ biggest markets, has slapped import bans on its manufacturing plants for failing to meet “good manufacturing practices”.
Click on the map below for details on each of the plants
In January 2014, US Food and Drug Administration prohibited Ranbaxy from producing or distributing any active pharmaceutical ingredients (APIs) from its Toansa planr for the US market, including drugs regulated by the FDA.
In September 2013, the FDA issued an import alert on Ranbaxy’s facility in Mohali, India, after “inspections identified significant CGMP violations.